share_log

石藥集團:翌日披露報表

CSPC PHARMA: NEXT DAY DISCLOSURES RETURNS

Hong Kong Stock Exchange ·  Apr 15 05:28
Summary by Moomoo AI
石藥集團有限公司於2024年4月15日提交了新的翌日披露報表,披露其已發行股本出現變動。該變動源於公司董事根據股份期權計劃行使期權,導致發行新股19,500,000股,佔公司於變動前已發行股份的0.16%。每股發行價為HKD 5.98,相較於上一個營業日的收市價HKD 5.94,溢價0.67%。此次股份發行後,石藥集團的已發行股本增至11,922,719,732股。公司確認,所有相關的法律及上市規定已遵守,並且所有條件已履行。
石藥集團有限公司於2024年4月15日提交了新的翌日披露報表,披露其已發行股本出現變動。該變動源於公司董事根據股份期權計劃行使期權,導致發行新股19,500,000股,佔公司於變動前已發行股份的0.16%。每股發行價為HKD 5.98,相較於上一個營業日的收市價HKD 5.94,溢價0.67%。此次股份發行後,石藥集團的已發行股本增至11,922,719,732股。公司確認,所有相關的法律及上市規定已遵守,並且所有條件已履行。
Petrochemical Group Limited filed a new Next Day Disclosure Report on April 15, 2024, disclosing the change in its issued share capital. The change resulted from the Company's directors exercising options under the Share Option Scheme, resulting in the issuance of 19,500,000 shares of the new shares, representing 0.16% of the company's shares issued prior to the change. The issue price per share is HKD 5.98, a premium of 0.67% compared to the closing price of HKD 5.94 on the previous business day. Following this share issue, the issued share capital of Petropharmaceuticals Group increased to 11,922,719,732 shares. The Company confirms that all relevant laws and listing requirements have been complied with and that all conditions have been met.
Petrochemical Group Limited filed a new Next Day Disclosure Report on April 15, 2024, disclosing the change in its issued share capital. The change resulted from the Company's directors exercising options under the Share Option Scheme, resulting in the issuance of 19,500,000 shares of the new shares, representing 0.16% of the company's shares issued prior to the change. The issue price per share is HKD 5.98, a premium of 0.67% compared to the closing price of HKD 5.94 on the previous business day. Following this share issue, the issued share capital of Petropharmaceuticals Group increased to 11,922,719,732 shares. The Company confirms that all relevant laws and listing requirements have been complied with and that all conditions have been met.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more